{"id":"cefaclor-capsules","safety":{"commonSideEffects":[{"rate":"3-10","effect":"Diarrhea"},{"rate":"1-3","effect":"Nausea"},{"rate":"1-2","effect":"Vomiting"},{"rate":"1-3","effect":"Rash"},{"rate":"1-2","effect":"Allergic reactions"},{"rate":"1-3","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefaclor works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has a broader spectrum of activity than first-generation cephalosporins, particularly against gram-negative organisms and some anaerobes, while maintaining good gram-positive coverage.","oneSentence":"Cefaclor is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:34.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media"}]},"trialDetails":[{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD PRESSURE DECREASED"},{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"CELLULITIS"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"EXPOSURE VIA BREAST MILK"},{"count":1,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"HYPERHIDROSIS"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cefaclor Capsules","genericName":"Cefaclor Capsules","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefaclor is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}